Amneal Pharmaceuticals, Inc.

As of June 30, 2026, Amneal Pharmaceuticals, Inc. Class A carries a market capitalization of 4.85B, placing it among publicly traded companies globally. Its enterprise value stands at 7.19B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Amneal Pharmaceuticals, Inc. Class A's next confirmed earnings release is scheduled for November 3, 2026.

As of June 30, 2026, Amneal Pharmaceuticals, Inc. Class A has 319.33M shares outstanding.

As of June 30, 2026, Amneal Pharmaceuticals, Inc. Class A trades at a trailing price-to-earnings ratio of 34.87. The price-to-sales ratio is 1.76, and the price-to-book ratio stands at 167.92.

As of June 30, 2026, Amneal Pharmaceuticals, Inc. Class A trades at an EV/EBITDA multiple of 12.66 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.63 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 18.09 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 7.19B versus a market cap of 4.85B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Amneal Pharmaceuticals, Inc. Class A maintains a current ratio of 2.20, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 8,453.73, indicating elevated leverage, while an interest coverage ratio of 2.85 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) stands at 4.37, measuring how efficiently the asset base is converted into earnings. The company generates approximately 322,933.70 in revenue per employee across its workforce of 8,450.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.94 indicates how many times Amneal Pharmaceuticals, Inc. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Amneal Pharmaceuticals, Inc. Class A recorded an income tax benefit of -12.38M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 176.09M, leaving 137.74M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Amneal Pharmaceuticals, Inc. Class A's stock has gained approximately 107.82% over the past 52 weeks. The 50-day moving average sits at 16.41, while the 200-day moving average is 13.46.

Over the twelve months ended June 30, 2026, Amneal Pharmaceuticals, Inc. Class A generated 2.73B in revenue and converted that into 137.74M in net income, yielding earnings per share of 0.58. EBITDA reached 567.38M, while operating income came in at 419.48M.

As of June 30, 2026, Amneal Pharmaceuticals, Inc. Class A holds 111.72M in cash and equivalents against 2.44B in total debt, resulting in a net debt position of 2.23B. Total book value stands at 28.91M, with working capital of 931.18M providing operational flexibility.

Amneal Pharmaceuticals, Inc. Class A produced 175.74M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -186.51M in capital expenditures, free cash flow totaled -10.77M - equivalent to -0.03 per share.

Over the twelve months ended June 30, 2026, Amneal Pharmaceuticals, Inc. Class A posted a gross margin of 39.32, reflecting its pricing power and cost economics. The operating margin of 15.37 and net profit margin of 5.05 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -0.22: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -1.26, meaning Amneal Pharmaceuticals, Inc. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Amneal Pharmaceuticals, Inc. Class A has an Altman Z-Score of 2.97, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.